The Chicago-based firm earlier announced that its two Phase II EMPOWER trials investigating emraclidine as a once-daily, oral ...

The US trade group Pharmaceutical Research and Manufacturers of America (PhRMA) today launched new advertisements urging ...

The US Food and Drug Administration (FDA) plays a pivotal role in fostering the development of treatments for rare diseases ...

Rubedo Life Sciences, a US biopharma developing first-in-class therapies targeting senescent cells which drive age-related diseases, has announced the appointment of Frederick C Beddingfield III ...

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

The combination of Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) and Citius Pharmaceuticals’ (Nasdaq: CTXR) Lymphir ...

Geron Corporation has secured $375 million to support the US and potential EU launch of Rytelo and pipeline development. The ...

Aurinia Pharmaceuticals (Nasdaq: AUPH) has announced a major strategic overhaul, reducing its workforce by almost half to focus on driving Lupkynis (voclosporin) growth. The changes, which will also ...

Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi ...

Almirall (BME: ALM), the Spain-based biopharma, reported a 7.9% increase in net sales for the first nine months of 2024, reaching 728 million euros ($775 million), and an EBITDA rise of 2.9% to $152 ...

According to the Swedish pharma trade group Lif, it is positive that, in the updated life science strategy, the government expresses an ambition for Sweden to become more attractive for research ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...